Post by Clement on Nov 3, 2021 7:30:48 GMT -5
finance.yahoo.com/news/united-therapeutics-corporation-reports-third-100000239.html
"The growth in Tyvaso revenues resulted primarily from an increase in quantities sold, reflecting an increased number of patients following the pulmonary hypertension associated with interstitial lung disease (PH-ILD) label expansion."
My comment: This bodes well for Tyvaso DPI and MNKD. UTHR is adding patients on Tyvaso-nebulizer and most of them will switch to Tyvaso DPI when approved next summer or earlier.
"The growth in Tyvaso revenues resulted primarily from an increase in quantities sold, reflecting an increased number of patients following the pulmonary hypertension associated with interstitial lung disease (PH-ILD) label expansion."
My comment: This bodes well for Tyvaso DPI and MNKD. UTHR is adding patients on Tyvaso-nebulizer and most of them will switch to Tyvaso DPI when approved next summer or earlier.
